04:07 AM EST, 11/07/2024 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) reported late Wednesday Q3 adjusted earnings of $0.62 per diluted share, up from $0.31 a year earlier.

Analysts polled by Capital IQ expected $0.37.

Revenue for the quarter ended Sep. 30 was $467.2 million, up from $331.8 million a year earlier.

Analysts polled by Capital IQ expected $405.1 million.